Merck & Co., Inc Dossier

Merck & Co., Inc generated trailing twelve-month revenue of $63.6 billion and reported operating income of $19.9 billion as of June 30, 2025, driven by the commercial scale of its Pharmaceutical segment and oncology portfolio. The company maintains a strong market presence through its diversified human and animal health divisions, underpinned by significant capital investments in manufacturing and strategic business development.

Financial Highlights

* Reported trailing twelve-month net income of $16.4 billion, resulting in a diluted EPS of $6.49.

* Generated total worldwide sales of $16.1 billion in the second quarter of 2025.

* Recorded Q2 2025 Keytruda sales of $7.96 billion, constituting a major portion of quarterly revenue.

* Achieved Pharmaceutical segment revenue of $14.1 billion for the quarter ending June 30, 2025.

* Posted Q2 2025 Animal Health revenue of $1.65 billion, derived from livestock and companion animal products.

* Maintained full-year 2025 revenue guidance in the range of $63.4 billion... Sign in / Sign up to learn more about Merck & Co., Inc

Continue your research by chatting with our AI financial analyst about Merck & Co., Inc. Ask follow-up questions, request specific analysis, or explore investment scenarios. All insights are grounded in verified financial data and SEC filings.

Start your analysis with these investor-focused questions:

• Given the contrasting performance in Q2 FY2025 with strong growth in Animal Health but a significant decline in Gardasil sales, how might these opposing trends within Merck & Co., Inc.'s segments influence its ability to achieve its full-year FY2025 financial guidance?
• With the major patent expiration for Keytruda looming, how effectively do Merck & Co., Inc.'s strategic actions in FY2025, such as the acquisition of Verona Pharma and pipeline advancements, position the company to mitigate this future revenue risk?
• Merck & Co., Inc. is simultaneously pursuing a $4.0 billion cost-saving initiative and a multi-billion dollar manufacturing expansion. How do these dual strategies impact its capital allocation priorities and projected operating margins for FY2025?
• Considering Merck & Co., Inc.'s forward P/E ratio of 9.74, what key performance drivers and risk factors in FY2025, such as the uptake of new products like Winrevair versus ongoing market challenges, will be most critical in determining if this valuation is justified?
• With an R&D intensity of nearly 28%, how does the commercial performance of Merck & Co., Inc.'s new launches in FY2025 contribute to validating its high research and development spending and its strategy for diversifying revenue streams beyond oncology?